843 related articles for article (PubMed ID: 19538975)
21. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
22. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system.
Dutra RC; Simão da Silva KA; Bento AF; Marcon R; Paszcuk AF; Meotti FC; Pianowski LF; Calixto JB
Neuropharmacology; 2012 Sep; 63(4):593-605. PubMed ID: 22613837
[TBL] [Abstract][Full Text] [Related]
23. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice.
Luongo L; Palazzo E; Tambaro S; Giordano C; Gatta L; Scafuro MA; Rossi FS; Lazzari P; Pani L; de Novellis V; Malcangio M; Maione S
Neurobiol Dis; 2010 Jan; 37(1):177-85. PubMed ID: 19804829
[TBL] [Abstract][Full Text] [Related]
24. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
25. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
Beltramo M; Bernardini N; Bertorelli R; Campanella M; Nicolussi E; Fredduzzi S; Reggiani A
Eur J Neurosci; 2006 Mar; 23(6):1530-8. PubMed ID: 16553616
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid receptors in conjunctival epithelium: identification and functional properties.
Iribarne M; Torbidoni V; Julián K; Prestifilippo JP; Sinha D; Rettori V; Berra A; Suburo AM
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4535-44. PubMed ID: 18566465
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
[TBL] [Abstract][Full Text] [Related]
28. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
[TBL] [Abstract][Full Text] [Related]
29. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
30. The antinociceptive effects of local injections of propofol in rats are mediated in part by cannabinoid CB1 and CB2 receptors.
Guindon J; LoVerme J; Piomelli D; Beaulieu P
Anesth Analg; 2007 Jun; 104(6):1563-9, table of contents. PubMed ID: 17513659
[TBL] [Abstract][Full Text] [Related]
31. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models.
Kohara A; Nagakura Y; Kiso T; Toya T; Watabiki T; Tamura S; Shitaka Y; Itahana H; Okada M
Eur J Pharmacol; 2007 Sep; 571(1):8-16. PubMed ID: 17597604
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
[TBL] [Abstract][Full Text] [Related]
33. Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
Chen L; Zhang J; Li F; Qiu Y; Wang L; Li YH; Shi J; Pan HL; Li M
J Pain; 2009 Jul; 10(7):732-9. PubMed ID: 19409856
[TBL] [Abstract][Full Text] [Related]
34. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
[TBL] [Abstract][Full Text] [Related]
35. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR
Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950
[TBL] [Abstract][Full Text] [Related]
36. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors.
Berger ND; Gadotti VM; Petrov RR; Chapman K; Diaz P; Zamponi GW
Mol Pain; 2014 Dec; 10():77. PubMed ID: 25481027
[TBL] [Abstract][Full Text] [Related]
37. The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors.
Nebane NM; Kellie B; Song ZH
FEBS Lett; 2006 Oct; 580(22):5392-8. PubMed ID: 16989818
[TBL] [Abstract][Full Text] [Related]
38. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].
La Rana G; Russo R; Campolongo P; Bortolato M; Mangieri RA; Cuomo V; Iacono A; Raso GM; Meli R; Piomelli D; Calignano A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1365-71. PubMed ID: 16510698
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
40. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.
Porreca F; Vanderah TW; Guo W; Barth M; Dodey P; Peyrou V; Luccarini JM; Junien JL; Pruneau D
J Pharmacol Exp Ther; 2006 Jul; 318(1):195-205. PubMed ID: 16565167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
